Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| HELIOS-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | Alnylam Pharmaceuticals. | Ongoing | ALN-TTRSC02 (Vutrisiran) | 3 | ALN-TTRSC02-003 | King Khalid University Hospital (Riyadh) |
| Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma | Roche | Completed | Bevacizumab | 3 | MO22923 | KFMC |
| Freeze dried kale to go, new superfood supplement to reduce metabolic risk in Saudi subjects | The National Plan for Science,Technology and Innovation | Ongoing | Freeze dried kale | 3 | H-01-R-002 | King Khalid University Hospital (Riyadh) |
| Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders | Bellicum Pharmaceuticals | Ongoing | Rimiducid | 1/2 | CT17-008-R | NGHA-R |
| Fluids in Septic Shock: A Randomized control Trial | McMaster University | Completed | Sodium Chloride | 3 | 20120802 | King Fahad University Hospital (Al-Khobar) |
| Fluids in Septic Shock (FISSH): a randomized controlled trial. | McMaster University | Ongoing | Normal Saline & Ringer's Lactate | 3 | 2211076 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 | KAIMRC | Ongoing | TOCILIZUMAB | 3 | RC20/225/R | King Abdulaziz Medical City NG (Riyadh) |
| Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 | KAIMRC | Ongoing | TOCILIZUMAB | 3 | RC20/225/R | King Abdulaziz Medical City NG (Riyadh) |
| Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) | Novartis | Completed | Nilotinib | 3b | CAMN107E2401 | KFSH |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis | Mast Therapeutics | Ongoing | Purified Poloxamer 188 | 3 | MST-188-01 | KKUH |